魏彦红

    【摘要】目的：观察对2型糖尿病患者予以卡格列净、吡格列酮联用治疗的有效性和安全性。方法：观察对象选择于2021年8月—2022年8月就诊于我院的2型糖尿病患者113例，随机方法施以分组观察，57例施以吡格列酮单用疗法者纳入对照组，56例施以卡格列净、吡格列酮联用治疗者纳入研究组，对治疗效果进行对比和观察。结果：与对照组(78.57%)对比，研究组治疗效果(98.25%)明显较好(P<0.05)；血糖水平治疗前两组对比(P>0.05)；与对照组对比，研究组治疗后血糖水平明显较好(P<0.05)；血清炎症因子治疗前两组对比(P>0.05)；与对照组对比，研究组治疗后血清炎症因子明显较低(P<0.05)；与对照组(19.64%)对比，研究组不良反应发生率(5.26%)明显较低(P<0.05)。结论：对2型糖尿病患者予以卡格列净、吡格列酮联用治疗有效性和安全性均较高，可使血清因子水平得以减轻，建议推广。

    【关键词】2型糖尿病；吡格列酮；卡格列净；不良反应；疗效

    Efficacy and adverse reactions of Cagliazine combined with pioglitazone in the treatment of type 2 diabetes mellitus

    WEI Yanhong

    The Second People’s Hospital of Baiyin， Gansu Province， Baiyin， Gansu 730900， China

    【Abstract】Objective： To observe the efficacy and safety of the combined treatment of cagliazine and pioglitazone in patients with type 2 diabetes mellitus. Methods： 113 patients with type 2 diabetes who were admitted to our hospital from February 2018 to February 2018 were randomly divided into groups. 57 patients receiving pioglitazone treatment alone were included in the control group ......